MedTech Asia is honored to have Dr. Akira Miyauchi, a visionary in thyroid treatment from Kuma Hospital, Japan, as the keynote speaker at our event.
His groundbreaking research in active surveillance for papillary thyroid microcarcinoma (PTMC) has revolutionized the approach to thyroid care, sparing thousands of patients from unnecessary surgery.
A Career Defined by Groundbreaking Research
Dr. Miyauchi, President and COO of Kuma Hospital, has dedicated over 30 years to researching and advocating for active surveillance in thyroid treatment. His approach has dramatically altered the management of low-risk thyroid cancer, emphasizing patient safety and quality of life.
Educational and Professional Background
Dr. Miyauchi’s extensive research and clinical work in thyroid care have made him a respected figure in the medical community. His leadership at Kuma Hospital, a center of excellence in thyroid care, reflects his commitment to advancing the field.
Pioneering Active Surveillance
Dr. Miyauchi’s proposal for active surveillance, initiated at Kuma Hospital in 1993, has been a game-changer in thyroid cancer treatment. This approach involves closely monitoring low-risk PTMC patients, avoiding immediate surgery, and thereby reducing the risks and complications associated with surgical intervention.
Impact of Research on Global Thyroid Care
Dr. Miyauchi’s research has had a profound impact on thyroid care globally. His studies have shown that active surveillance can safely manage low-risk PTMC, leading to a significant shift in treatment paradigms worldwide.
At MedTech Asia
As the keynote speaker at MedTech Asia, Dr. Miyauchi will share his extensive knowledge and experience in active surveillance. His insights are invaluable to medical professionals seeking to adopt more patient-centric approaches in thyroid care.
Global Recognition and Contributions
Dr. Miyauchi’s contributions to thyroid care have earned him international recognition. His advocacy for active surveillance has influenced treatment guidelines and practices across the globe, making him a leading authority in the field.
Dr. Akira Miyauchi’s keynote address at MedTech Asia represents a unique opportunity for attendees to learn from a pioneer in thyroid care. His dedication to research, patient safety, and innovative treatment approaches has transformed the management of thyroid conditions, making him an esteemed figure in the medical community.
Introduction to MedTech Asia
Why MedTech Asia? More than just a thyroid ablation congress, MedTech Asia stands out by showcasing the world’s top thyroid ablation experts from the Americas, Europe, and Asia. Its highlight is the treatment of 20 Thai patients, who lack the means for such care, serving as a live demonstration platform for thyroid ablation techniques to conference attendees.